drugset / Trial / NCT04555304
Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of the study drug known as KH903 in participants with gastric and gastroesophageal cance
Timeline
- Start
- 2020-09-15
- Primary completion
- 2022-01-15
- Completion
- 2022-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KH903 | Unknown | 4 mg/kg | Intravenous |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |